This new paradigm of personalized medicine will break the cycle of 'trial and error medicine, and link the test to patient tailored action and evidence based therapy/ treatment plan. Multiple gene testing will be more cost effective in terms of changing therapy regimen, stratifying responders vs. non responders to drugs etc.
Using genomic markers for chemo-sensitivity/ chemo-resistance may dramatically improve response rates to chemotherapy, significantly impacting the risk-benefit ratio for these patients.
The tests will also help to detect the hereditary cancer: examples include testing for mutations in BRCA1or BRCA2 in unaffected women to identify those at significantly elevated risk for developing breast and ovarian cancers, colon, thyroid and other cancers. A potential tool for screening patients with newly diagnosed cancers and their family members for risk predisposition to reduce morbidity and mortality.
|Sr. No.||Test Description||Benefits of NGS Based Cancer Mutation Panel Testing|
|1||Germline Mutation Panel [Single or multiple cancer type or total 86 genes]||Predict risk, risk estimation, institute early surveillance measures|
|2||Somatic Mutation Panel [48 genes hot spot panel]||Selection of therapy, indicate responsiveness to chemotherapy, sensitivity to a particular therapy|
|3||Colorectal Cancer Panel [APC, BRAF, EGFR, KRAS, MET, NRAS, PIK3CA, PTEN, SMAD4]||Indicates appropriate FDA approved/NCCN recommanded therapy (Cetuximab, Panitumumab, Bevacizumab, 5-FU, Oxaliplatin)|
|4||NSCLC Panel [Alk (by FISH), BRAF, EGFR, ERBB2 (Her2), KRAS, MET, PIK3CA, VHL]||Indicates appropriate FDA approved/NCCN recommanded therapy (Erlotinib, Afatinib, Trastuzumab, Bevacizumab, Crizotinib, Ceritinib, Vemurafenib, Dabrafenib)|
|5||Breast Cancer Panel [ERBB2 (Her2), EGFR, PTEN, PIK3CA, SMAD4, VHL]||Indicates appropriate FDA approved/NCCN recommanded therapy (Trastuzumab, Pertuzumab, Lapatinib, Evrolimus, Tamoxifen, 5-FU, Bevacizumab)|